MAPT and Alzheimer disease: Recently, an 18F-labeled PBB3 derivative, [18F]Florzolotau (also known as [18F]APN1607 and [18F]PM-PBB3), was developed and shown to improve the imaging properties of [11C]PBB3 with broader accessibility and a higher signal-to-noise ratio for detecting tau pathologies in both human and animal studies (Hsu et al., 2020; Su et al., 2020; Lu et al., 2020; Tagai et al., 2021), and in non-AD tauopathies (Li et al., 2021; Liu et al., 2023).